Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Peter Crooks to Drug Delivery Systems

This is a "connection" page, showing publications Peter Crooks has written about Drug Delivery Systems.

 
Connection Strength
  
 
 
1.453
  
  1. Eldridge JA, Milewski M, Stinchcomb AL, Crooks PA. Synthesis and in vitro stability of amino acid prodrugs of 6-?-naltrexol for microneedle-enhanced transdermal delivery. Bioorg Med Chem Lett. 2014 Nov 15; 24(22):5212-5.
    View in: PubMed
    Score: 0.433
  2. Al-Ghananeem AM, Crooks PA. Phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery. Molecules. 2007 Mar 08; 12(3):373-88.
    View in: PubMed
    Score: 0.256
  3. Zheng G, Dwoskin LP, Crooks PA. Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J. 2006 Nov 10; 8(4):E682-92.
    View in: PubMed
    Score: 0.250
  4. Nickell JR, Siripurapu KB, Vartak A, Crooks PA, Dwoskin LP. The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Adv Pharmacol. 2014; 69:71-106.
    View in: PubMed
    Score: 0.103
  5. Banks SL, Pinninti RR, Gill HS, Paudel KS, Crooks PA, Brogden NK, Prausnitz MR, Stinchcomb AL. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs. J Pharm Sci. 2010 Jul; 99(7):3072-80.
    View in: PubMed
    Score: 0.081
  6. Milewski M, Yerramreddy TR, Ghosh P, Crooks PA, Stinchcomb AL. In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin. J Control Release. 2010 Aug 17; 146(1):37-44.
    View in: PubMed
    Score: 0.080
  7. Geldenhuys WJ, Manda VK, Mittapalli RK, Van der Schyf CJ, Crooks PA, Dwoskin LP, Allen DD, Lockman PR. Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporter. Bioorg Med Chem Lett. 2010 Feb 01; 20(3):870-7.
    View in: PubMed
    Score: 0.078
  8. Kiptoo PK, Paudel KS, Hammell DC, Hamad MO, Crooks PA, Stinchcomb AL. In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs. Eur J Pharm Sci. 2008 Apr 23; 33(4-5):371-9.
    View in: PubMed
    Score: 0.068
  9. Kiptoo PK, Hamad MO, Crooks PA, Stinchcomb AL. Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion. J Control Release. 2006 Jun 28; 113(2):137-45.
    View in: PubMed
    Score: 0.060
  10. Howard-Sparks M, Al-Ghananeem AM, Crooks PA, Pearson AP. A novel chemical delivery system comprising an ocular sustained release formulation of a 3alpha, 17alpha, 21-trihydroxy-5beta-pregnan-20-one-BIS-5-fluorouracil [correction of flourouracil] codrug. Drug Dev Ind Pharm. 2007 Jun; 33(6):677-82.
    View in: PubMed
    Score: 0.016
  11. Vaddi HK, Hamad MO, Chen J, Banks SL, Crooks PA, Stinchcomb AL. Human skin permeation of branched-chain 3-0-alkyl ester and carbonate prodrugs of naltrexone. Pharm Res. 2005 May; 22(5):758-65.
    View in: PubMed
    Score: 0.014
  12. Valiveti S, Hammell DC, Paudel KS, Hamad MO, Crooks PA, Stinchcomb AL. In vivo evaluation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. J Control Release. 2005 Feb 02; 102(2):509-20.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.